ClinicalTrials.gov record
Recruiting Phase 2 Interventional

Safety, PK, PD, Dosing, and Efficacy of RLS-0071for the Treatment of Hospitalized Patients With Steroid-Refractory Acute Graft-versus-Host Disease

ClinicalTrials.gov ID: NCT06343792

Public ClinicalTrials.gov record NCT06343792. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 4, 2026, 11:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase 2 Open Label Prospective Dose-Ranging Clinical Trial With Escalation and Expansion Cohorts to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Dosing, and Efficacy of RLS-0071 for the Treatment of Hospitalized Patients With Steroid-Refractory Acute Graft-versus-Host Disease

Study identification

NCT ID
NCT06343792
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 2
Lead sponsor
ReAlta Life Sciences, Inc.
Industry
Enrollment
66 participants

Conditions and interventions

Interventions

  • RLS-0071 Drug

Drug

Eligibility (public fields only)

Age range
12 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 30, 2024
Primary completion
Nov 30, 2026
Completion
Nov 30, 2026
Last update posted
Nov 23, 2025

2024 – 2026

United States locations

U.S. sites
6
U.S. states
4
U.S. cities
6
Facility City State ZIP Site status
Site 1091 Duarte California 91010 Active, not recruiting
Site 1343 Los Angeles California 90095 Active, not recruiting
Site 1318 Atlanta Georgia 30041 Active, not recruiting
Site 1068 St Louis Missouri 63110 Active, not recruiting
Site 1100 Cincinnati Ohio 45229 Active, not recruiting
Site 1382 Columbus Ohio 43210 Active, not recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 5 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06343792, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 23, 2025 · Synced May 4, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06343792 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →